Clinical Trials
2 trialsNCT03793166 2026-05-29
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05504642 2023-04-18
CERAD-IMMUNE
Universitätsklinikum Köln
Phase 2 Withdrawn